Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) was the target of a large drop in short interest in the month of January. As of January 15th, there was short interest totalling 535,000 shares, a drop of 21.4% from the December 31st total of 680,800 shares. Based on an average daily trading volume, of 636,800 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.8% of the shares of the stock are short sold.
Tiziana Life Sciences Stock Down 0.6 %
Shares of Tiziana Life Sciences stock traded down $0.00 during trading on Friday, reaching $0.68. The company's stock had a trading volume of 44,427 shares, compared to its average volume of 1,189,127. The business has a 50 day moving average price of $0.82 and a 200-day moving average price of $0.94. Tiziana Life Sciences has a 12-month low of $0.41 and a 12-month high of $1.74.
Institutional Investors Weigh In On Tiziana Life Sciences
An institutional investor recently raised its position in Tiziana Life Sciences stock. Zhang Financial LLC increased its stake in shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA - Free Report) by 34.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 93,187 shares of the company's stock after buying an additional 23,800 shares during the period. Zhang Financial LLC owned about 0.09% of Tiziana Life Sciences worth $65,000 as of its most recent filing with the Securities and Exchange Commission.
About Tiziana Life Sciences
(
Get Free Report)
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
Featured Stories
Before you consider Tiziana Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.
While Tiziana Life Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
